Advanced

Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.

Herweijer, Eva; Leval, Amy; Ploner, Alexander; Eloranta, Sandra; Simard, Julia Fridman; Dillner, Joakim LU ; Netterlid, Eva LU ; Sparén, Pär and Arnheim-Dahlström, Lisen (2014) In JAMA: the journal of the American Medical Association 311(6). p.597-603
Abstract
Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Condylomata Acuminata: epidemiology, Condylomata Acuminata: prevention & control, Papillomavirus Infections: prevention & control, Papillomavirus Vaccines: administration & dosage, Registries: statistics & numerical data, Sweden: epidemiology, Uterine Cervical Neoplasms: prevention & control, Vaccination: statistics & numerical data
in
JAMA: the journal of the American Medical Association
volume
311
issue
6
pages
597 - 603
publisher
American Medical Association
external identifiers
  • pmid:24519299
  • wos:000330941000015
  • scopus:84893666624
ISSN
1538-3598
DOI
10.1001/jama.2014.95
language
English
LU publication?
yes
id
dc33635d-238f-466e-b344-255141fe2306 (old id 4334812)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24519299?dopt=Abstract
date added to LUP
2014-03-06 10:24:42
date last changed
2017-03-19 04:21:38
@article{dc33635d-238f-466e-b344-255141fe2306,
  abstract     = {Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.},
  author       = {Herweijer, Eva and Leval, Amy and Ploner, Alexander and Eloranta, Sandra and Simard, Julia Fridman and Dillner, Joakim and Netterlid, Eva and Sparén, Pär and Arnheim-Dahlström, Lisen},
  issn         = {1538-3598},
  keyword      = {Condylomata Acuminata: epidemiology,Condylomata Acuminata: prevention & control,Papillomavirus Infections: prevention & control,Papillomavirus Vaccines: administration & dosage,Registries: statistics & numerical data,Sweden: epidemiology,Uterine Cervical Neoplasms: prevention & control,Vaccination: statistics & numerical data},
  language     = {eng},
  number       = {6},
  pages        = {597--603},
  publisher    = {American Medical Association},
  series       = {JAMA: the journal of the American Medical Association},
  title        = {Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.},
  url          = {http://dx.doi.org/10.1001/jama.2014.95},
  volume       = {311},
  year         = {2014},
}